SCHEMBL6684556

SCHEMBL6684556

CN1C(=O)C(Cc2cccc(F)c2)C(=O)c2cc(C(=O)NCc3ccc(F)cc3)ccc21

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.49
ALDH1A1 P00352 2/20 0.47
LMNA P02545 3/20 0.46
MAPT P10636 3/20 0.46
RXFP1 Q9HBX9 2/20 0.46
THRB P10828 2/20 0.46
EPHX2 P34913 1/20 0.44
PPARG P37231 1/20 0.44
DRD3 P35462 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HTR7 P34969 1/20 0.43
POLB P06746 1/20 0.43
ROCK2 O75116 2/20 0.43
BRD4 O60885 1/20 0.43
GAA P10253 1/20 0.42
ROCK1 Q13464 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6664648 0.92 ALDH1A1 (0.49) DRD2ALDH1A1LMNAMAPTRXFP1
SCHEMBL6685126 0.92 THRB (0.48) DRD2ALDH1A1MAPTRXFP1THRB
SCHEMBL6681355 0.90 HTR7 (0.49) DRD2ALDH1A1LMNAMAPTRXFP1
SCHEMBL6664863 0.88 DRD2 (0.46) DRD2ALDH1A1LMNAMAPTRXFP1
SCHEMBL6666902 0.88 TP53 (0.47) DRD2ALDH1A1LMNAMAPTRXFP1
SCHEMBL6680610 0.87 DRD2 (0.45) DRD2ALDH1A1LMNAMAPTRXFP1
SCHEMBL6668774 0.87 DRD2 (0.45) DRD2ALDH1A1LMNAMAPTRXFP1
SCHEMBL6665657 0.86 ALDH1A1 (0.60) DRD2ALDH1A1LMNAMAPTTHRB
SCHEMBL6664500 0.84 NR1H2 (0.41) ALDH1A1MAPTMEN1KMT2AHTR7
SCHEMBL6686372 0.81 ALDH1A1 (0.49) DRD2ALDH1A1MAPTRXFP1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed
WO-2004014388-A1 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 DRD2 1883/4885ALDH1A1 1202/4885LMNA 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.